Mixed CARE-MS I data – Good for BIIB!
Sanofi/GENZ’s Lemtrada (alemtuzumab, PhIII, RRMS) met the primary end point (reduction in relapse rate), but secondary endpoint- time to six month sustained accumulation of disability (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players in the MS field? Please read our report, released on 11th July, 2011, titled – “Mixed CARE-MS I data – Good for BIIB!”
COMPANIES MENTIONED
BIOGEN IDEC
BIOGEN IDEC
More Publications
New Technologies Initiative: Gateway to Treating Genetic Diseases - Sarepta Therapeutics - Skipping Makes Sense - Restoring Muscle Function in Duchenne Muscular Dystrophy
US$ 500.00
March 2013
18 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
October 2011
4 pages
Brisotl-Myers Squibb - Eliquis Approved for SPAF in Europe – Waiting for decision with FDA
US$ 90.00
November 2012
2 pages
PFIZER – MERCK alliance for Ertugliflozin – Not a better partner than Merck
US$ 90.00
April 2013
2 pages
BMY Suspended dosing of Inhibitex HCV drug - Valuations stretched and there is no room for negative news
US$ 90.00
August 2012
2 pages
